FDA rejects Sandoz's Neulasta copy, giving Amgen a break from the biosim onslaught

Amgen’s ($AMGN) aging superstars have been under assault lately by Novartis’ ($NVS) Sandoz unit and its biosimilars ambitions. But the Big Biotech scored a break at the hands of regulators: The FDA rebuffed Sandoz's biosim version of Amgen's blockbuster Neulasta, Novartis disclosed Tuesday.

Within its Q2 results, Novartis revealed that its Neulasta biosimilar candidate had been turned down by the FDA, which issued a complete response letter after accepting the company’s application last November.

“We are working with the agency to address remaining questions,” the Swiss pharma giant said, without providing details.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

It’s good news for Amgen, which has so far been the only victim of Sandoz’s biosimilar trailblazing in the U.S. Last year, Sandoz became the first to hit the U.S. market with a biosim--Zarxio, a copy of Amgen’s Neupogen--and it has also taken aim at the drugmaker’s anti-TNF giant Enbrel. An FDA advisory committee last week recommended that the agency green light Sandoz's copy in all of Enbrel’s approved indications.

Now, the California company has at least a bit more time to keep Neulasta’s blockbuster haul all to itself. Amgen’s No. 2 seller, behind Enbrel, Neulasta netted $4.72 billion in sales last year, with $3.89 billion of that coming in the U.S.

It’s not the first time the FDA has rejected an Amgen knockoff, either. Last October, regulators turned away Pfizer’s ($PFE) Hospira unit, which was seeking to pass muster with a biosimilar version of kidney disease drug Epogen.

And while the regulatory hurdles won’t keep biosimilars at bay forever, they’ll help keep Amgen’s top line stable while it pursues a biosimilar agenda of its own. It’s currently working to snag an OK for its copy of AbbVie’s ($ABBV) worldwide bestseller Humira, and last week that med scored backing from an FDA advisory panel.

- read the release

Special Report: Top 20 generics companies by 2014 revenue - Novartis - Sandoz

Related Articles:
Sandoz Enbrel biosim cruises at FDA panel, endangering key Amgen sales
In unanimous vote, FDA committee backs Amgen's Humira biosim
Novartis' Sandoz aims for 5 biosim launches by 2020
Novartis takes a third biosimilar shot at Amgen with a copy of the blockbuster Neulasta
Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do?

Suggested Articles

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.